Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-30T20:12:34.482Z Has data issue: false hasContentIssue false
  • English
  • Français

High-dose desvenlafaxine in outpatients with major depressive disorder

Published online by Cambridge University Press:  10 August 2012

James M. Ferguson ,
Karen A. Tourian  and
Gregory R. Rosas
James M. Ferguson*
Affiliation:
University of Utah School of Medicine, Salt Lake City, Utah, USA
Karen A. Tourian
Affiliation:
Wyeth Research, A Company of the Pfizer Group, Paris, France
Gregory R. Rosas
Affiliation:
Pfizer Inc., formerly Wyeth Research, Collegeville, Pennsylvania, USA
*
*Address for correspondence: James Ferguson, MD, Clinical Professor, Psychiatry, University of Utah School of Medicine, 1611 Federal Heights Drive, Salt Lake City, UT 84103, USA. (Email [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective

This study investigated the safety and efficacy of long-term treatment with high-dose desvenlafaxine (administered as desvenlafaxine succinate) in major depressive disorder (MDD).

Methods

In this multicenter, open-label study, adult outpatients with MDD aged 18–75 were treated with flexible doses of desvenlafaxine (200–400 mg/d) for ≤ 1 year. Safety assessments included monitoring of treatment-emergent adverse events (TEAEs), patient discontinuations due to adverse events, electrocardiograms, vital signs, and laboratory determinations. The primary efficacy measure was mean change from baseline in the 17-item Hamilton Rating Scale for Depression [HAM-D(17)] total score.

Results

The mean daily desvenlafaxine dose range over the duration of the trial was 267–356 mg (after titration). The most frequent TEAEs in the safety population (n = 104) were nausea (52%) and headache (41%), dizziness (31%), insomnia (29%), and dry mouth (27%). All TEAEs were mild or moderate in severity. Thirty-four (33%) patients discontinued from the study because of TEAEs; nausea (12%) and dizziness (9%) were the most frequently cited reasons. The mean change in HAM-D(17) total score for the intent-to-treat population (n = 99) was −9.9 at the last on-therapy visit in the last-observation-carried-forward analysis and −14.0 at month 12 in the observed cases analysis.

Conclusion

High-dose desvenlafaxine (200–400 mg/d) was generally safe and effective in the long-term treatment of MDD.

Keywords

Depressiondesvenlafaxineoutpatients
Type
Original Research
Information
CNS Spectrums , Volume 17 , Issue 3 , September 2012 , pp. 121 - 130
Copyright
Copyright © Cambridge University Press 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

This study was sponsored by Wyeth Research, which was acquired by Pfizer Inc. in October 2009. The authors wish to thank S. Krishna Padmanabhan of Pfizer (formerly Wyeth) for statistical support in connection with the study and manuscript development. We also thank Susan M. Adamczyk, MS, of On Assignment for her professional medical writing and editorial assistance, which was funded by Wyeth. Additional medical writing support for this manuscript was provided by Carol Grimes, PhD, at Embryon, LLC, a division of Advanced Health Media, LLC, and Lorraine Sweeney, BA, at Embryon and Peloton Advantage LLC, and was funded by Pfizer Inc.

References

1.World Health Organization. Depression. Available at: http://www.who.int/mental_health/management/depression/definition/en/print.html. Accessed June 11, 2008.Google Scholar
2.American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV, 4th ed.Washington, DC: American Psychiatric Association; 1994.Google Scholar
3. American Psychiatric Association. Work Group on Major Depressive Disorder. Practice guideline for the treatment of patients with major depressive disorder. American Psychiatric Association. Available at: http://www.psych.org/guidelines/mdd2010. Accessed February 1, 2012.Google Scholar
4.Kessler, RC, Berglund, P, Demler, O, et al. . The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23): 3095–3105.CrossRefGoogle ScholarPubMed
5.Sheehan, DV. Depression: underdiagnosed, undertreated, underappreciated. Manag Care. 2004; 13(suppl 6): 6–8.Google ScholarPubMed
6.Lingam, R, Scott, J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002; 105(3): 164–172.CrossRefGoogle ScholarPubMed
7.Demyttenaere, K, Van, GE, Gregoire, J, et al. . Compliance in depressed patients treated with fluoxetine or amitriptyline. Belgian Compliance Study Group. Int Clin Psychopharmacol. 1998; 13(1): 11–17.CrossRefGoogle ScholarPubMed
8.Demyttenaere, K, Enzlin, P, Dewe, W, et al. . Compliance with antidepressants in a primary care setting, 1: Beyond lack of efficacy and adverse events. J Clin Psychiatry. 2001; 62(suppl 22): 30–33.Google Scholar
9.Oganesian, A, Shilling, AD, Young-Sciame, R, et al. . Desvenlafaxine and venlafaxine exert minimal in vitro inhibition of human cytochrome P450 and P-glycoprotein activities. Psychopharmacol Bull. 2009; 42(2): 47–63.Google ScholarPubMed
10.Boyer, P, Montgomery, S, Lepola, U, et al. . Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. Int Clin Psychopharmacol. 2008; 23(5): 243–253.CrossRefGoogle Scholar
11.DeMartinis, NA, Yeung, PP, Entsuah, R, Manley, AL. A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. J Clin Psychiatry. 2007; 68(5): 677–688.CrossRefGoogle ScholarPubMed
12.Liebowitz, MR, Manley, AL, Padmanabhan, SK, et al. . Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. Curr Med Res Opin. 2008; 24(7): 1877–1890.CrossRefGoogle ScholarPubMed
13.Septien-Velez, L, Pitrosky, B, Padmanabhan, SK, et al. . A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2007; 22(6): 338–347.CrossRefGoogle ScholarPubMed
14.Thase, ME, Kornstein, SG, Germain, JM, et al. . An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. CNS Spectr. 2009; 14(3): 144–154.CrossRefGoogle ScholarPubMed
15.Sheehan, DV, Lecrubier, Y, Sheehan, KH, et al. . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 59(suppl 20): 22–33.Google ScholarPubMed
16.Hamilton, M. Hamilton rating scale for depression (Ham-D). In: Rush AJ, Pincus HA, First MB, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000: 526–529.Google Scholar
17.Montgomery, SA, Asberg, M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134: 382–389.CrossRefGoogle ScholarPubMed
18.DeLoach, LJ, Higgins, MS, Caplan, AB, Stiff, JL. The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg. 1998; 86(1): 102–106.Google ScholarPubMed
19.Sheehan, DV. Sheehan Disability Scale. In: Rush AJ, Pincus HA, First MB, eds. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000: 113–115.Google Scholar
20.World Health Organization. Wellbeing measures in primary health care/the depcare project. World Health Organization Regional Office for Europe. Available at: http://www.euro.who.int/__data/assets/pdf_file/0016/130750/E60246.pdf. Accessed March 20, 2012.Google Scholar
21.Clayton, AH, Kornstein, SG, Rosas, G, Guico-Pabia, C, Tourian, KA. An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. CNS Spectr. 2009; 14(4): 183–195.CrossRefGoogle ScholarPubMed
22. Pristiq [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc; 2011.Google Scholar
23. Paxil [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2006.Google Scholar
24. Prozac [package insert]. Indianapolis, IN: Eli Lilly and Company; 2011.Google Scholar
25. Celexa [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.; 2011.Google Scholar
26. Effexor XR [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2006.Google Scholar
27. Cymbalta [package insert]. New York, NY: Eli Lilly and Company; 2005.Google Scholar
28. Zoloft [package insert]. New York, NY: Roerig; 2006.Google Scholar
29.Thase, ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry. 1998; 59(10): 502–508.CrossRefGoogle ScholarPubMed
30.Kocsis, JH, Thase, ME, Trivedi, MH, et al. . Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT Study. J Clin Psychiatry. 2007; 68(7): 1014–1023.CrossRefGoogle Scholar
31.Detke, MJ, Wiltse, CG, Mallinckrodt, CH, et al. . Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol. 2004; 14(6): 457–470.CrossRefGoogle ScholarPubMed
32.Fava, M. Weight gain and antidepressants. J Clin Psychiatry. 2000; 61(suppl 11): 37–41.Google ScholarPubMed
33.Al-Khatib, SM, LaPointe, NM, Kramer, JM, Califf, RM. What clinicians should know about the QT interval. JAMA. 2003; 289(16): 2120–2127.CrossRefGoogle ScholarPubMed
34.Isbister, GK, Bowe, SJ, Dawson, A, Whyte, IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol. 2004; 42(3): 277–285.CrossRefGoogle ScholarPubMed
35.Stahl, SM, Grady, MM, Moret, C, Briley, M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr. 2005; 10(9): 732–747.CrossRefGoogle ScholarPubMed
36.Davey, P. How to correct the QT interval for the effects of heart rate in clinical studies. J Pharmacol Toxicol Methods. 2002; 48(1): 3–9.CrossRefGoogle Scholar
37.Dunlop, BW, Reddy, S, Yang, L, et al. . Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo. J Clin Psychopharmacol. 2011; 31(5): 569–576.CrossRefGoogle ScholarPubMed